Thromboreductin 0,5 mg Capsules
PDF Leaflet Revision Date: 3 January 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of essential thrombocythaemia to reduce platelet count.
Dosage (summary)
Start with 0.5 mg daily, increase weekly by 0.5 mg; usual maintenance 1.5-3 mg daily.
Onset of Action / Duration
Onset: 2 weeks, Duration: up to 5 mg daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Aspirin (increased bleeding risk)
- CYP1A2 inhibitors
- QTc prolonging agents
Contraindications
- Hypersensitivity to anagrelide
- Severe renal insufficiency
- Moderate to severe hepatic insufficiency
- Cardiovascular disease grade 3 or 4
Common side effects
- Headaches
- Palpitations
- Oedema
- Nausea
- Diarrhoea
Counselling Points
- Monitor platelet counts regularly
- Avoid abrupt treatment discontinuation
- Report signs of thrombotic events
Serious warnings
- Risk of thrombotic complications upon treatment discontinuation
- Serious cardiovascular events reported
On This Page
Loading package insert…
Medinsert AI
Hello! I am Medinsert Ai. What would you like to know about this professional information leaftleft?
